Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a 300-page biotech filing isn’t easy—especially when Phio Pharmaceuticals� disclosures dive deep into RNAi chemistry, IND milestones and financing rounds. If you’ve ever searched the 10-K for cash-runway details or hunted through Form 4s to see when executives buy shares ahead of INTASYL trial data, you know the challenge.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR and delivers plain-English answers to the questions investors actually ask: “Phio Pharmaceuticals SEC filings explained simply� and “understanding Phio Pharmaceuticals SEC documents with AI.� Quickly jump from an “Item 1A-Risk Factors� headline to a one-sentence summary, or set real-time alerts for “Phio Pharmaceuticals Form 4 insider transactions real-time.� You’ll also find:
- Complete Phio Pharmaceuticals annual report 10-K simplified—cash burn, R&D spend and INTASYL pipeline updates distilled by AI.
- Every Phio Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side trend charts.
- Immediate access to Phio Pharmaceuticals 8-K material events explained—from trial results to financing announcements.
- Detailed Phio Pharmaceuticals proxy statement executive compensation breakdowns.
The result: faster insight into PH-762 progress, better tracking of Phio Pharmaceuticals insider trading Form 4 transactions, and the context you need to act decisively. Whether you’re scanning Phio Pharmaceuticals earnings report filing analysis or monitoring Phio Pharmaceuticals executive stock transactions Form 4, our platform keeps you ahead of the curve—without wading through biotech jargon.
Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.
The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.
Phio Pharmaceuticals Corp. (PHIO) filed a Form D announcing a Rule 506(b) private placement that opened 28-Jul-2025.
- Target size: up to $5.08 million in warrants and the underlying common shares.
- Raised to date: $232,149 (�4.6% of target) from two accredited investors; minimum investment $0.
- Remaining to sell: $4.85 million.
- Broker compensation: $261,753 cash (�5.2% of capital raised) plus 69,645 warrants (7,500 exercisable at $2.8125; 62,145 at $3.4188).
- Securities offered: options/warrants and the shares issuable upon exercise; no debt or pooled-fund interests.
- Offering duration: expected to close within one year; not linked to a business combination.
- Issuer profile: Delaware-incorporated biotechnology company headquartered in King of Prussia, PA; revenue size undisclosed.
No proceeds are slated for payments to directors, officers or promoters. Reliance on Reg D limits the sale to accredited investors and keeps detailed financials private. Execution risk remains until the full amount is subscribed.
Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.
Key details:
- Carson has been appointed as VP, Finance and Administration at Phio Pharmaceuticals
- Currently holds no beneficial ownership of any securities, either direct or indirect
- Filing includes no derivative securities ownership (options, warrants, etc.)
- Individual filing submitted with Power of Attorney documentation (Exhibit 24)
This Form 3 establishes the baseline ownership position for the new officer's future transaction reporting requirements under SEC Section 16(a).
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
